Paxmedica grants exclusive pharmacy distribution rights for pax-101 to vox nova, llc

�   agreement for pax-101 (suramin iv) distribution in the u.s. for up to 7 years ·   voxnova will be responsible for physician registration, safety monitoring and reimbursement for treatment, as well as additional offerings for people diagnosed with autism and their families tarrytown, ny and hudson, oh, july 06, 2023 (globe newswire) -- via newmediawire – paxmedica, inc. (nasdaq: pxmd) and vox nova llc (voxnova), a privately held corporation, today announced that they have signed an exclusive pharmacy distribution agreement for paxmedica's lead pipeline asset, pax-101.   paxmedica is a clinical stage, biopharmaceutical company, focused on the development of novel anti-purinergic drug therapies for the treatment of autism spectrum disorder (asd), and other serious conditions with intractable neurological symptoms.
PXMD Ratings Summary
PXMD Quant Ranking